key: cord-0713761-fzzr1b4q authors: Zhang, Wenjing; Li, Lei; Liu, Jihai; Chen, Li; Zhou, Fangfang; Jin, Ting; Jiang, Lin; Li, Xiang; Yang, Ming; Wang, Hongxiang title: The characteristics and predictive role of lymphocyte subsets in COVID-19 patients date: 2020-08-03 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2020.06.079 sha: 27354d67b83f0afc481f819699fe7282deb404fe doc_id: 713761 cord_uid: fzzr1b4q Abstract Objective To investigate the characteristics and predictive roles of lymphocyte subsets in COVID-19 patients. Method We evaluated lymphocyte subsets and other clinical features of COVID-19 patients and analysed their potential impacts on COVID-19 outcomes. Results 1. Lymphocyte subset counts in the peripheral blood of patients with COVID-19 were significantly reduced, especially in patients with severe disease. 2. In patients with non-severe diseases, the time from symptom onset to hospital admission was positively correlated with total T cell counts. 3. Among COVID-19 patients who did not reach the composite endpoint, lymphocyte subset counts were higher than in patients who had reached the composite endpoint. 4. The Kaplan-Meier survival curves showed significant differences in COVID-19 patients, classified by the levels of total, CD8+ and CD4+ T cells at admission. Conclusion Our study shows that the total, CD8+ and CD4+ T cell counts in patients with COVID-19 were significantly reduced, especially in patients with severe disease. T lymphocyte subsets were significantly associated with a higher occurrence of composite endpoint events. These subsets may help identify patients with a high risk of composite endpoint events. an exponential rate. Currently, COVID-19 has spread to more than 200 countries and regions around the world. As of 6 June, 2020, there were 6772520 confirmed cases and 393843 deaths from COVID-19 (WHO, 2020b; Onder et al., 2020) . Previous studies on the clinical characteristics of COVID-19 have shown that patients with COVID-19 may have mild or severe symptoms of acute respiratory infection; patients with mild disease have symptoms such as fever, dry cough, fatigue and abnormal chest CT, but their prognosis is good. In contrast, some patients' conditions progress rapidly and develop into acute respiratory distress syndrome (ARDS) or even multiple organ failure (MOF) in a very short time (Wu et al., 2020) . According to different research reports, the mortality rate is between 2.3% and 15% (Wu et al., 2020; Huang et al., 2020) . Immune factors may play an important role in the rapid progression of this disease. Therefore, studying the role of immune factors is important for the early identification of patients with severe COVID-19 and timely intervention is very important for control of the disease. In this study, we retrospectively reviewed the clinical and laboratory data of 90 patients with COVID-19 diagnosed in the Central Hospital of Wuhan from January to March 2020. We examined the association of lymphocyte subsets with the progression and prognosis of COVID-19 patients. This was a retrospective single-center study recruiting patients admitted to the Central Hospital of Wuhan, which is close to the Huanan seafood market and was one of the first designated hospitals to receive COVID-19 patients. We conducted a retrospective analysis of patients diagnosed with COVID-19 from January to March. All patients were positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by quantitative RT-PCR (qRT-PCR). Patients who were still hospitalized after March 16, 2020, were excluded. Ultimately, 90 confirmed COVID-19 patients were included in the analyses. Patients were divided into a non-severe cohort and a severe cohort according to their condition. All COVID-19 patients were classified as having non-severe to severe disease at admission according to the COVID-19 Guidelines (seventh version) made by the National Health Commission of the People's Republic of China. With regard to the classification criteria, patients with mild disease presented with mild symptoms and exhibited normal radiology findings in both lungs. Patients with moderate (typical) disease presented typical symptoms (fever, cough and other respiratory symptoms) and radiology manifestations suggesting pneumonia. Patients with severe disease presented with any one of the following: 1) respiratory distress, defined as a respiratory rate ≥30 breaths per minute; 2) a pulse oxygen saturation ≤93% on room air; or 3) an oxygenation index (PaO2/FiO2) ≤300 mmHg. Critically ill patients presented with any one of the following: 1) respiratory failure for which invasive ventilation was necessary, 2) signs of shock (circulatory failure), or 3) failure of any other organ such that ICU care was necessary. The non-severe cohort included patients with mild and moderate disease, and the severe cohort included patients with severe disease and critically ill patients. This study was approved by the Ethics Committees of the Central Hospital of Wuhan. As this study was a retrospective analysis of electronic data, no informed consent was obtained. The composite endpoint included admission to the intensive care unit (ICU), mechanical ventilation, or death. Based on this, patients were divided into a composite endpoint group and a non-composite endpoint group. We collected data on age, sex, smoking history, the time from symptom onset to hospital admission, symptoms from onset to hospital admission (fever, mild shortness of breath, cough, expectoration, fatigue, diarrhea, myalgia), complications during hospitalization (ARDS, bacterial infection, septic shock, liver damage), laboratory findings at admission (lymphocyte subsets counts, leukocyte counts, neutrophil counts, lymphocyte counts, monocyte counts, hemoglobin concentrations, platelet J o u r n a l P r e -p r o o f counts, hypersensitive C-reactive protein levels, procalcitonin levels, lactate dehydrogenase levels, partially activated prothrombin time, prothrombin time, fibrinogen levels, D-dimer levels and PaO2 / FiO2 level), computed tomography (CT) scans at admission. SPSS 22.0 statistical analysis software was used for data analysis. The Shapiro-Wilk normality test and the variance homogeneity test were used for measurement data. The measurement data with normal distribution are described by the mean ± standard deviation, and the skewed data with nonnormal distribution are described by the median (P25-P75). The differences between the two endpoint groups were compared. The measurement data with normal distribution and homogeneity of variance were compared between groups by a two independent samples t-test. The measurement data satisfying the normal distribution but not the homogeneity of variance criteria were compared between groups by the Satterthwaite t-test. According to the applicable conditions, the chi-square test, corrected chi-square test and Fisher's exact probability method were used. The Spearman rank test was used to analyse the correlations between measurement data. The influence of lymphocyte subsets on composite endpoint events was analysed by stepwise forward logistic regression. ROC curves were used to calculate the cut-off point to classify the T lymphocyte subsets. Then, Kaplan-Meier survival curves were used to analyse the influence of immune parameters on the occurrence of composite endpoint events; an α=0.05 was considered significant. A total of 61 patients (67.78%) had fever before admission. Most of the patients had pneumonia symptoms, including fatigue (33.33%), expectoration (31.1%), cough J o u r n a l P r e -p r o o f (30%) and mild shortness of breath (23.33%). Only 11.11% of the patients had diarrhea. Compared with patients with non-severe disease, those with severe disease were more likely to have fever, fatigue, expectoration and myalgia. (Table 1) . There was no significant difference in age, sex and smoking history between severe and non-severe group. All patients underwent chest CT examination at admission. The most common abnormality was bilateral pneumonia (66, 73.3%) ( Table 1 ). During hospitalization, the incidence of complications (acute respiratory distress syndrome, bacterial infection, septic shock, liver damage) in severe group was higher than that in non-severe group. Compared with those of non-severe COVID-19 patients, the laboratory parameters of severe COVID-19 patients on admission, including hematological indicators (WBCs, lymphocyte and platelet counts), coagulation function parameters (fibrinogen and D-dimer levels), infection-related biomarkers (CRP, procalcitonin and LDH levels) and PaO2 / FiO2 level showed extensive and significant differences ( Table 2) . Among non-severe COVID-19 patients, the median total T cell, CD8 + T cell, CD4 + T cell, NK cell and total B cell counts were 1170, 430, 670, 210 and 150, respectively, while the median values decreased to 380, 180, 180, 80 and 80, respectively, in severe COVID-19 patients. The counts of total T cells, CD8 + T cells, CD4 + T cells, NK cells and total B cells were significantly lower in patients with severe disease than in patients with non-severe disease (Figure 1 ). In patients with non-severe disease, the time from symptom onset to hospital admission was positively correlated with total T cell counts (r=0.251,P<0.05), while other lymphocyte subsets showed no significant correlation with the time from symptom onset to hospital admission (Table 3, Figure 2) J o u r n a l P r e -p r o o f During hospitalization, patient treatments mainly included antiviral therapy (81.1%), antibiotic therapy (82.2%), glucocorticoids (35.6%), and immunoglobulin (35.6%). The common antiviral treatments included Arbidol(67.8%), oseltamivir (24.4%), lopinavir and ritonavir (5.6%) and interferon (16.7%), and more than onethird of patients took more than one antiviral drug. High-flow oxygen therapy was required in 13 patients (14.4%). Invasive mechanical ventilation was required in 5 patients (5.6%), and 10 patients (11.1%) were admitted to the ICU. As of March 16, 87 (96.7%) patients were discharged, and 3 (3.3%) patients died. Among COVID-19 patients who did not reach the composite endpoint, the median total T cell, CD8 + T cell, CD4 + T cell, NK cell and total B cell counts were 1090, 400, 610, 190 and 150, respectively, while the median values decreased to 290, 130, 170, 60 and 90, respectively, in patients who reached the composite endpoint. The counts of total T cells, CD8 + T cells, CD4 + T cells, NK cells and total B cells were significantly lower in patients who reached the composite endpoint than in patients who did not reach the composite endpoint ( Figure 3 ). Stepwise forward logistic regression was used to measure the potential association between lymphocyte subsets and composite endpoints. We found that lower total T cell counts were associated with a higher risk of composite endpoint events (OR=0.001,95% CI [0.000,0.038], P=0.001) ( Table 4 ). In addition, total, CD8 + and CD4 + T cells were selected as candidate markers to predict composite endpoints. The area under the ROC curve was 0.935 (95% confidence interval [CI], 0.857-1.000) for total T cell counts, 0.864 (95% CI, 0.761-0.967) for CD8 + T cell counts and 0.926 (95% CI, 0.825-1.000) for CD4 + T cell counts. Moreover, cut-off values, including for total T cells (585), CD8 + T cells (325) and CD4 + T cells (202), were calculated according to the ROC curve (Figure 4) .The Kaplan-Meier survival curves showed that lower levels of total, CD8 + and CD4 + T cells at admission were associated with higher occurrences of the composite endpoint events in COVID-19 patients ( Figure 5 ). In this study, the severity and progression of COVID-19 and the T lymphocyte subsets were studied. We present some novel findings. First, lymphocyte subsets are associated with COVID-19 severity and progression. Second, in patients with nonsevere disease, total T cell counts recovered as the number of days past disease onset increased. Finally, total, CD8 + and CD4 + T cell counts could serve as risk factors for fatal outcomes of COVID-19. We describe a cohort of 90 COVID-19 patients who were hospitalized in the Central Hospital of Wuhan. According to the COVID-19 Guidelines (seventh version), 20 out of 90 patients were included in the severe group, accounting for approximately 22.2% of the total cases, similar to the situations in previous studies (Wu et al., 2020) . The clinical features of patients with COVID-19 have recently been reported (Wu et al., 2020; Huang et al., 2020; Chen et al., 2020) . The most common clinical manifestations at the onset of illness included fever, fatigue, expectoration, cough and mild shortness of breath. Severe cases were more likely than non-severe cases to have fever, expectoration, fatigue and to develop ARDS. Our study indicated that the total, CD8 + and CD4 + T cell counts in the peripheral blood of patients with COVID-19 were significantly reduced, especially in patients J o u r n a l P r e -p r o o f with severe disease. Postmortem findings have shown that lymphocyte counts in the spleen and lymph nodes are significantly reduced, including CD8 + T and CD4 + T cell counts.The increases in the levels of the cytokine IL-6 were more significant in patients with severe disease than in those with non-severe disease and were negatively correlated with the number of T subsets(data not shown), consistent with previous results (Bo et al, 2020) . This may be related to a systemic inflammatory response caused by a cytokine storm, similar to that observed in SARS patients. In COVID-19 patients, T cell overactivation and T cell exhaustion may exist simultaneously. In COVID-19 patients, CD4 + T cells are highly active, the absolute numbers of CD4 + T cells are decreased, and secretion of IFN-r is weakened; in addition, T cell exhaustion is more obvious in patients with severe disease than in those with non-severe disease (Chen et al., 2020) . In viral infections, coexpression of Tim-3 and PD-1 may indicate severe exhaustion of T cells. The levels of PD-1 and Tim-3 in T cells of patients with COVID-19 are significantly higher than those in T cells of healthy controls. Increased expression of PD-1 and Tim-3 in T cells can be used as a marker for progression from the prodromal to the obviously symptomatic stage, further indicating T cell exhaustion (Bo et al., 2020) . Excessive activation of T cells, characterized by increases in Th17 populations and high cytotoxicity of CD8 + T cells, may be part of the cause of immune injury in patients (Xu et al., 2020) . It has been reported that after SARS-CoV-2 infection, CD4 + T lymphocytes are rapidly activated into pathogenic T helper (Th) 1 cells. Then, the pathogenic Th1 cells become activated and secrete proinflammatory cytokines such as IL-6. Inflammatory monocytes are activated and proliferate, and the activated immune cells enter the pulmonary circulation, leading to serious lung injury. Blocking GM-CSF or IL-6 may inhibit immunopathological injury (Yonggang et al., 2020) . Therefore, monitoring of lymphocyte subsets and cytokines can provide early warnings of severe disease in patients. According to an expert consensus statement from Shanghai, the early warning indicators of severe disease in patients include J o u r n a l P r e -p r o o f CD4 + T lymphocyte numbers < 250/μL and significantly increased levels of IL-6 in blood. In addition, it is recommended to detect lymphocyte subsets and IL-6 at least once every three days. During clinical treatment, if IL-6 levels are increased, patients can be given the IL-6 receptor monoclonal antibody tocilizumab. If lymphocyte or CD4 + T cell counts are decreased, patients can be treated with thymosin. In this study, we observed that in patients with non severe disease, the number of days past onset at admission were correlated with higher total T cell counts. In severe patients, it can be observed that the more days past onset at admission, the lower the lymphocyte subset counts, but the differences were not statistically significant. The possible reasons for the non significant results are as follows: 1. The number of selected cases in this study is relatively small. 2. The total number of lymphocytes is low in patients with severe disease, which leads to little significant difference. Through studies on immune indicators, some scholars observed that the changes in T lymphocytes in the course of disease were closely related to the severity of COVID-19 (Wang et al., 2020 , He et al.,2020 . Studies have shown that immune factors after coronavirus infection play an important role in the progression of the disease. The acquired immunity produced by the body to the coronavirus is necessary for effective viral clearance. It has been reported that the number of CD4 + T cells may help predict the clearance of viral RNA. Fewer CD4 + T cells before treatment led to slower clearance of the virus (Ling et al., 2020). We found that the lymphocyte subset counts in patients who reached the composite endpoint were significantly lower than those counts in patients who did not reach the composite endpoint. We found that lower total T cell counts were associated with a higher risk of composite endpoint events. Our data also showed that the numbers of total, CD8 + and CD4 + T cells were closely related to the occurrence of composite endpoint events in these patients, suggesting that the T cells could act as independent risk factors for the clinical prognosis of these patients. Our study has several limitations. First, it was a retrospective study, so there could have been systematic selection bias. Second, due to the shortage of medical resources and the urgency of time during the outbreak of the epidemic in Wuhan, there is no condition for detection of virus load in patients. Third, in the future, a multicenter follow-up study with a larger cohort is urgently needed. In conclusion, our study shows that the total, CD8 + and CD4 + T cell counts in the peripheral blood of patients with COVID-19 were significantly reduced, especially in patients with severe disease. The total, CD8 + and CD4 + T cells were significantly associated with higher occurrence of composite endpoint event. Our findings support T cell counts were significant differences between the non-severe and severe groups，and may help identify patients with high risk to occur composite endpoint events. The study was approved by the Ethics Committees of the Central Hospital of Wuhan. As this study was a retrospective analysis of electronic data, no informed consent was obtained. The author declare that they have no conflicts of interest. The data are shown as the median value (interquartile range). Abbreviation: WBC, white blood cell; APTT, Activated partial thromboplastin time; PT, prothrombin time; CRP, C-reactive protein; LDH, lactate dehydrogenase. A Novel Coronavirus from Patients with Pneumonia in China Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia World Health Organization World Health Organization Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy Characteristics of and Important Lessons From the COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical and immunologic features in severe and moderate Coronavirus Disease Pathological findings of COVID-19 associated with acute respiratory distress syndrome Aberrant pathogenic GM-CSF + T cells and inflammatory CD14 + CD16 + monocytes in severe pulmonary syndrome patients of a new coronavirus Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia The clinical course and its correlated immune status in COVID-19 pneumonia Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients